SRD5A1 and prostate cancer: Among men with the homozygous wild-type genotype (CC) at SNP locus rs8192166 in the hormone-associated gene Steroid Reductase 5-alpha-1 (SRD5A1), we observed a reduced risk of prostate cancer among men who reported low use of dicamba (OR = 0.62, 95% CI: 0.41, 0.93) and high use of dicamba (OR = 0.44, 95% CI: 0.29, 0.68), as compared to those who reported no use of dicamba (Table 3).